Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Farah LatifHira Bint Abdul JabbarHamna MalikHumaira SadafPiero SchiròZouina SarfrazIván Cherrez-OjedaPublished in: Expert review of anticancer therapy (2022)
We collate evidence of atezolizumab/pembrolizumab as viable therapeutics among patients with TNBC with PD-L1 subgroups deriving higher benefits.